CYP2C19

CYP2C19 is a human cytochrome P450 enzyme that contributes to oxidative drug metabolism and interindividual pharmacokinetic variability^[1]. Mechanistically, CYP enzymes also participate in arachidonic acid epoxygenase pathways that generate epoxyeicosatrienoic acids, linking monooxygenase biology with lipid signaling research^[2]. In disease-relevant pharmacology, CYP2C19 catalyzes clopidogrel bioactivation, and reduced-function phenotypes show reduced platelet inhibition and increased cardiovascular or cerebrovascular event risk during clopidogrel therapy^[3]. Compared with related isoforms, CYP2C19 differs structurally from CYP2C8 and CYP2C9 in active-site architecture, supporting isoform-selective substrate recognition^[4]. Direct comparison with CYP2C9 further shows distinct variant abundance patterns in substrate-recognition regions, providing experimental models for mapping isoform-specific function^[5]. For research applications, proton pump inhibitors serve as clinically important CYP2C19 substrates because most PPIs are metabolized primarily by CYP2C19 into inactive metabolites, and genotype data guide exposure-focused study design^[6].